Back to Search
Start Over
Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
- Source :
-
Gynecologic oncology [Gynecol Oncol] 2024 May; Vol. 184, pp. 89-95. Date of Electronic Publication: 2024 Jan 31. - Publication Year :
- 2024
-
Abstract
- Objectives: The longer-term impact of introducing human papillomavirus (HPV) testing into routine cervical cancer screening on precancer and cancer rates by histologic type has not been well described. Calendar trends in diagnoses were examined using data from Kaiser Permanente Northern California, which introduced triennial HPV and cytology co-testing in 2003 for women aged ≥30 years.<br />Methods: We examined trends in cervical precancer (cervical intraepithelial neoplasia grade 3 [CIN3] and adenocarcinoma in situ [AIS]) and cancer (squamous cell carcinoma [SCC] and adenocarcinoma [ADC]) diagnoses per 1000 screened during 2003-2018. We examined ratios of squamous vs. glandular diagnoses (SCC:ADC and CIN3:AIS).<br />Results: CIN3 and AIS diagnoses increased approximately 2% and 3% annually, respectively (p <subscript>trend</subscript>  < 0.001 for both). While SCC diagnoses decreased by 5% per annually (p <subscript>trend</subscript>  < 0.001), ADC diagnoses did not change. These patterns were generally observed within each age group (30-39, 40-49, and 50-64 years). ADC diagnoses per 1000 screened did not change even among those who underwent co-testing starting in 2003-2006. SCC:ADC decreased from approximately 2.5:1 in 2003-2006 to 1.3:1 in 2015-2018 while the CIN3:AIS remained relatively constant, ∼10:1.<br />Conclusions: Since its introduction at KPNC, co-testing increased the detection of CIN3 over time, which likely caused a subsequent reduction of SCC. However, there has been no observed decrease in ADC. One possible explanation for lack of effectiveness against ADC is the underdiagnosis of AIS. Novel strategies to identify and treat women at high risk of ADC need to be developed and clinically validated.<br />Competing Interests: Declaration of competing interest Dr. Castle has received HPV tests and assays for research at a reduced cost from Atila Biosystems in the last 3 years.<br /> (Published by Elsevier Inc.)
- Subjects :
- Humans
Female
California epidemiology
Adult
Middle Aged
Carcinoma, Squamous Cell diagnosis
Carcinoma, Squamous Cell epidemiology
Carcinoma, Squamous Cell pathology
Carcinoma, Squamous Cell virology
Adenocarcinoma in Situ pathology
Adenocarcinoma in Situ diagnosis
Adenocarcinoma in Situ epidemiology
Adenocarcinoma in Situ virology
Precancerous Conditions diagnosis
Precancerous Conditions epidemiology
Precancerous Conditions virology
Precancerous Conditions pathology
Aged
Vaginal Smears trends
Vaginal Smears methods
Adenocarcinoma diagnosis
Adenocarcinoma epidemiology
Adenocarcinoma pathology
Adenocarcinoma virology
Human Papillomavirus Viruses
Cytodiagnosis
Uterine Cervical Neoplasms diagnosis
Uterine Cervical Neoplasms virology
Uterine Cervical Neoplasms epidemiology
Uterine Cervical Neoplasms pathology
Uterine Cervical Dysplasia diagnosis
Uterine Cervical Dysplasia epidemiology
Uterine Cervical Dysplasia virology
Uterine Cervical Dysplasia pathology
Early Detection of Cancer methods
Early Detection of Cancer statistics & numerical data
Early Detection of Cancer trends
Papillomavirus Infections diagnosis
Papillomavirus Infections epidemiology
Papillomavirus Infections pathology
Papillomavirus Infections virology
Subjects
Details
- Language :
- English
- ISSN :
- 1095-6859
- Volume :
- 184
- Database :
- MEDLINE
- Journal :
- Gynecologic oncology
- Publication Type :
- Academic Journal
- Accession number :
- 38301311
- Full Text :
- https://doi.org/10.1016/j.ygyno.2024.01.038